Julie Papanek Net Worth

The estimated Net Worth of Julie Papanek is at least $110 Million dollars as of 16 August 2016. Julie Papanek owns over 583,333 units of Protagonist Therapeutics Inc stock worth over $109,881,291 and over the last 8 years Julie sold PTGX stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Julie Papanek PTGX stock SEC Form 4 insiders trading

Julie has made over 1 trades of the Protagonist Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Julie bought 583,333 units of PTGX stock worth $6,999,996 on 16 August 2016.

The largest trade Julie's ever made was buying 583,333 units of Protagonist Therapeutics Inc stock on 16 August 2016 worth over $6,999,996. On average, Julie trades about 194,444 units every 0 days since 2016. As of 16 August 2016 Julie still owns at least 2,453,255 units of Protagonist Therapeutics Inc stock.

You can see the complete history of Julie Papanek stock trades at the bottom of the page.

What's Julie Papanek's mailing address?

Julie's mailing address filed with the SEC is 521 Cottonwood Dr, Milpitas, CA 95035, USA.

Insiders trading at Protagonist Therapeutics Inc

Over the last 8 years, insiders at Protagonist Therapeutics Inc have traded over $11,629,969 worth of Protagonist Therapeutics Inc stock and bought 3,007,840 units worth $35,519,073 . The most active insiders traders include Capital Partners Gp, L.L.C...., & Johnson Johnson & Johnson..., and X L.P.Canaan Partners X Llc.... On average, Protagonist Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $2,387,307. The most recent stock trade was executed by William D. Waddill on 24 July 2024, trading 8,000 units of PTGX stock currently worth $103,040.

What does Protagonist Therapeutics Inc do?

protagonist therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform which is utilized to discover and develop novel peptide-based drugs to address significant unmet medical needs. its primary focus is on developing potential first-in-class oral targeted therapy-based peptide drugs that work by blocking biological pathways that are currently targeted by marketed injectable antibody drugs. protagonist's initial lead peptide product candidates, ptg-100 and ptg-200, are based on this approach, and the company believes these candidates have the potential to transform the existing treatment paradigm for inflammatory bowel disease (ibd), consisting primarily of ulcerative colitis and crohn's disease. ptg-100, a potential first-in-class oral peptide alpha-4-beta-7 integrin antagonist, is currently in a global phase 2b clinical trial for treatment of moderate-to-severe ulcerative colitis. ptg-200, a first-in-class oral interleukin-23 receptor antagonist

Complete history of Julie Papanek stock trades at Protagonist Therapeutics Inc

Protagonist Therapeutics Inc executives and stock owners

Protagonist Therapeutics Inc executives and other stock owners filed with the SEC include:

• Dinesh Patel,
  President, Chief Executive Officer, Director
• Suneel Gupta,
  Chief Development Officer
• David Liu,
  Chief Scientific Officer, Head of Research & Development
• Dr. Dinesh V. Patel Ph.D.,
  CEO, Pres, Interim PAO, Sec. & Director
• Dr. David Y. Liu,
  Chief Scientific Officer and Head of Discovery & Pre-Clinical Devel.
• Dr. Suneel K. Gupta Ph.D.,
  Chief Devel. Officer
• Harold Selick,
  Independent Chairman of the Board
• William Waddill,
  Independent Director
• Bryan Giraudo,
  Independent Director
• Sarah Noonberg,
  Independent Director
• Lewis Williams,
  Independent Director
• Sarah O'Dowd,
  Independent Director
• Brian Korb,
  IR Contact Officer
• Samuel Saks,
  Chief Medical Officer
• Donald Kalkofen,
  Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
• Asif Ali,
  Exec. VP & Chief Financial Officer
• Dr. Scott Eric Plevy M.D.,
  Exec. VP and Therapeutic Head of Gastroenterology
• Dr. Ashok Bhandari Ph.D.,
  Sr. VP of Discovery Chemistry & Process Research
• Mohammad Masjedizadeh,
  Exec. VP & CTO
• Donald A. Kalkofen,
  Chief Financial Officer
• Dr. Larry Mattheakis,
  Sr. VP of Discovery Biology & Translational Research
• Dr. Ashok Bhandari,
  Sr. VP of Discovery Chemistry & Process Research
• Carena Spivey,
  Exec. Director of HR
• Matthew M. Gosling,
  Exec. VP & Gen. Counsel
• Dr. Mark Smythe,
  Founder & VP Technology
• Dr. Richard S. Shames,
  Clinical Advisor
• Arturo Md Molina,
  Chief Medical Officer
• Armen Shanafelt,
  Director
• Chaitan Phd Khosla,
  Director
• Julie Papanek,
  Director
• Richard S. Shames,
  Chief Medical Officer
• Thomas P. O'neil,
  Chief Financial Officer
• William A Hodder,
  Sr. VP - Corporate Development
• & Johnson Johnson & Johnson...,
  
• X L.P.Canaan Partners X Llc...,
  
• Management Group, Llc Lilly...,
  
• Asif Ali,
  Chief Financial Officer
• Capital Partners Gp, L.L.C....,
  
• Daniel N Jr Swisher,
  Director